{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:08:04Z","timestamp":1792631284113,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"DOI":"10.7759\/cureus.100927","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:24:47Z","timestamp":1767716687000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Aymen A","family":"Alqurain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashayer A","family":"Algarzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M","family":"Eljadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem S","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Almuhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deema S","family":"Albuhayji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joud","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Alsayyali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nessreen","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay T","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gharam G","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. International Diabetes Federation, Brussels; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/db24-0688","article-title":"Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type 2 diabetes, based on baseline renal function","volume":"74","author":"Wang Y","year":"2025","unstructured":"Wang Y, Xia C, Li M, Xu G. Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type 2 diabetes, based on baseline renal function. Diabetes. 2025, 74:672-81. 10.2337\/db24-0688","journal-title":"Diabetes"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Jiang L, Wang J, et al.. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022, 21:232. 10.1186\/s12933-022-01676-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12020183","article-title":"Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies","volume":"12","author":"Caruso I","year":"2022","unstructured":"Caruso I, Cignarelli A, Sorice GP, Natalicchio A, Perrini S, Laviola L, Giorgino F. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites. 2022, 12:183. 10.3390\/metabo12020183","journal-title":"Metabolites"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-025-00248-2","article-title":"Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","volume":"11","author":"Shokravi A","year":"2025","unstructured":"Shokravi A, Seth J, Lu N, Mancini GB. Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis. Cardiovasc Diabetol Endocrinol Rep. 2025, 11:37. 10.1186\/s40842-025-00248-2","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston D","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, et al.. Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes. J Am Coll Cardiol. 2024, 84:696-708. 10.1016\/j.jacc.2024.06.016","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo EM","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, et al.. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024, 12:545-57. 10.1016\/S2213-8587(24)00155-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1011535","article-title":"Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status","volume":"9","author":"Du L","year":"2022","unstructured":"Du L, Li Z, Lan P, Huang H, Cheng W. Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status. Front Cardiovasc Med. 2022, 9:1011535. 10.3389\/fcvm.2022.1011535","journal-title":"Front Cardiovasc Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14741","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"24","author":"Dong YH","year":"2022","unstructured":"Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab. 2022, 24:1623-37. 10.1111\/dom.14741","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84137","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in reducing cardiovascular events in patients with type 2 diabetes","volume":"17","author":"Khan HU","year":"2025","unstructured":"Khan HU, Akhtar B, Singla B, et al.. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in reducing cardiovascular events in patients with type 2 diabetes. Cureus. 2025, 17:e84137. 10.7759\/cureus.84137","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno E","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG, et al.. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021, 44:826-35. 10.2337\/dc20-1464","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams N","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, et al.. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024, 385:e078242. 10.1136\/bmj-2023-078242","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, et al.. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley &amp; Sons, London; 2019. 10.1002\/9781119536604"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","article-title":"Introduction to Meta-Analysis","author":"Borenstein M","year":"2021","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley, Hoboken, NJ; 2021. 10.1002\/9780470743386"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref16","article-title":"Meta-Analysis With R","author":"Schwarzer G","year":"2015","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G. Meta-Analysis With R. Springer, Cham; 2015."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/0470870168","article-title":"Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments","author":"Rothstein HR","year":"2005","unstructured":"Rothstein HR, Sutton AJ, Borenstein M. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. John Wiley &amp; Sons, Chichester; 2005. 10.1002\/0470870168"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/0470870168.ch13","article-title":"Assessing the evolution of effect sizes over time","author":"Trikalinos TA","year":"2005","unstructured":"Trikalinos TA, Ioannidis JPA. Assessing the evolution of effect sizes over time. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Rothstein HR, Sutton AJ, Borenstein M (ed): John Wiley &amp; Sons, Chichester; 2005. 241-59. 10.1002\/0470870168.ch13"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/0470870168.ch5","article-title":"The funnel plot","author":"Sterne JAC","year":"2005","unstructured":"Sterne JAC, Becker BJ, Egger M. The funnel plot. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Rothstein HR, Sutton AJ, Borenstein M (ed): John Wiley &amp; Sons, Chichester; 2005. 75-98. 10.1002\/0470870168.ch5"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/0470870168.ch6","article-title":"Regression methods to detect publication and other bias in meta-analysis","author":"Sterne JAC","year":"2005","unstructured":"Sterne JAC, Egger M. Regression methods to detect publication and other bias in meta-analysis. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Rothstein HR, Sutton AJ, Borenstein M (ed): John Wiley &amp; Sons, Chichester; 2005. 99-110. 10.1002\/0470870168.ch6"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/0470870168.ch12","article-title":"Bias in meta-analysis induced by incompletely reported studies","author":"Sutton AJ","year":"2005","unstructured":"Sutton AJ, Pigott TD. Bias in meta-analysis induced by incompletely reported studies. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Rothstein HR, Sutton AJ, Borenstein M (ed): John Wiley &amp; Sons, Chichester; 2005. 221-39. 10.1002\/0470870168.ch12"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/0470870168.ch9","article-title":"Selection method approaches","author":"Hedges LV","year":"2005","unstructured":"Hedges LV, Vevea J. Selection method approaches. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Rothstein HR, Sutton AJ, Borenstein M (ed): John Wiley &amp; Sons, Chichester; 2005. 145-74. 10.1002\/0470870168.ch9"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14343","article-title":"Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: analyses from the LYDIA trial","volume":"23","author":"Ahmad E","year":"2021","unstructured":"Ahmad E, Waller HL, Sargeant JA, et al.. Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: analyses from the LYDIA trial. Diabetes Obes Metab. 2021, 23:1409-14. 10.1111\/dom.14343","journal-title":"Diabetes Obes Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.07.007","article-title":"Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial","volume":"288","author":"Anholm C","year":"2019","unstructured":"Anholm C, Kumarathurai P, Pedersen LR, et al.. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial. Atherosclerosis. 2019, 288:60-6. 10.1016\/j.atherosclerosis.2019.07.007","journal-title":"Atherosclerosis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon CP","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al.. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020, 383:1425-35. 10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al.. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021, 384:129-39. 10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer MA","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al.. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015, 373:2247-57. 10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman RR","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al.. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017, 377:1228-39. 10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez AF","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al.. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018, 392:1519-29. 10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019, 394:131-8. 10.1016\/S0140-6736(19)31150-X","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain M","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al.. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019, 381:841-51. 10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein HC","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al.. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021, 385:896-907. 10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink HJ","year":"2021","unstructured":"Heerspink HJ, Sj\u00f6str\u00f6m CD, Jongs N, et al.. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021, 42:1216-27. 10.1093\/eurheartj\/ehab094","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:323-34. 10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner C","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al.. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018, 137:119-29. 10.1161\/CIRCULATIONAHA.117.028268","journal-title":"Circulation"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic V","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al.. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018, 6:691-704. 10.1016\/S2213-8587(18)30141-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon O","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al.. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019, 7:606-17. 10.1016\/S2213-8587(19)30180-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051901","article-title":"Gradient of risk and associations with cardiovascular efficacy of ertugliflozin by measures of kidney function: observations from VERTIS CV","volume":"143","author":"Cherney DZ","year":"2021","unstructured":"Cherney DZ, McGuire DK, Charbonnel B, et al.. Gradient of risk and associations with cardiovascular efficacy of ertugliflozin by measures of kidney function: observations from VERTIS CV. Circulation. 2021, 143:602-5. 10.1161\/CIRCULATIONAHA.120.051901","journal-title":"Circulation"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002484","article-title":"Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial","volume":"9","author":"Dagogo-Jack S","year":"2021","unstructured":"Dagogo-Jack S, Pratley RE, Cherney DZ, et al.. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care. 2021, 9:e002484. 10.1136\/bmjdrc-2021-002484","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris G","year":"2020","unstructured":"Bakris G, Oshima M, Mahaffey KW, et al.. Effects of canagliflozin in patients with baseline eGFR &lt;30 ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol. 2020, 15:1705-14. 10.2215\/CJN.10140620","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine MJ","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, et al.. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020, 31:1128-39. 10.1681\/ASN.2019111168","journal-title":"J Am Soc Nephrol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet MH","year":"2018","unstructured":"Muskiet MH, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJ, van Raalte DH. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018, 6:859-69. 10.1016\/S2213-8587(18)30268-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial","volume":"41","author":"Dhatariya K","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB, et al.. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial. Diabetes Care. 2018, 41:2229-35. 10.2337\/dc18-1094","journal-title":"Diabetes Care"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter LA","year":"2019","unstructured":"Leiter LA, Bain SC, Hramiak I, et al.. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019, 18:73. 10.1186\/s12933-019-0871-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel MA","year":"2020","unstructured":"Bethel MA, Mentz RJ, Merrill P, et al.. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care. 2020, 43:446-52. 10.2337\/dc19-1065","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453329-comparative-effectiveness-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-versus-glucagon-like-peptide-1-glp-1-agonists-on-cardiovascular-and-renal-outcomes-in-type-2-diabetes-a-systematic-review-and-network-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:24:48Z","timestamp":1767716688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453329-comparative-effectiveness-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-versus-glucagon-like-peptide-1-glp-1-agonists-on-cardiovascular-and-renal-outcomes-in-type-2-diabetes-a-systematic-review-and-network-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.100927","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}